Neurofilament light as a prognostic marker in multiple sclerosis
- PMID: 20086018
- DOI: 10.1177/1352458509359725
Neurofilament light as a prognostic marker in multiple sclerosis
Abstract
Relapsing-remitting multiple sclerosis has a variable prognosis and lacks a reliable laboratory prognostic marker. Our aim in this study was to investigate the association between neurofilament light levels in cerebrospinal fluid in early multiple sclerosis and disease severity at long-term follow-up. Neurofilament light levels in cerebrospinal fluid collected at diagnostic lumbar puncture were measured in 99 multiple sclerosis cases. Clinical data were obtained from 95 out of those at follow-up visits made 14 years (range 8-20 years) after disease onset. Significant correlations between neurofilament light levels and the multiple sclerosis severity score were found for all cases (r = 0.30, p = 0.005), for relapsing-remitting multiple sclerosis cases (r = 0.47, p < 0.001) and for cases with a recent relapse (r = 0.60, p < 0.001). In the multivariate logistic regression analysis, neurofilament light levels >386 ng/L (median value of cases with detectable levels) increased the risk for severe multiple sclerosis fivefold (odds ratio 5.2, 95% confidence interval 1.8-15). Kaplan-Meier analysis showed that conversion to secondary-progressive multiple sclerosis was more likely in cases with neurofilament light levels >386 ng/L than in those with neurofilament light levels <60 ng/L (p = 0.01) or 60-386 ng/L (p = 0.03). We conclude that elevated levels of neurofilament light in cerebrospinal fluid collected at diagnostic lumbar puncture were associated with unfavourable prognosis. These data suggest that the neurofilament light level could be used as a prognostic marker in early relapsing-remitting multiple sclerosis.
Comment in
-
Cerebrospinal fluid neurofilament: the biomarker that will resuscitate the 'Spinal Tap'.Mult Scler. 2010 Mar;16(3):285-6. doi: 10.1177/1352458510361358. Mult Scler. 2010. PMID: 20203146 No abstract available.
Similar articles
-
Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.Mult Scler. 2011 Mar;17(3):303-11. doi: 10.1177/1352458510386996. Epub 2010 Nov 15. Mult Scler. 2011. PMID: 21078694
-
Tau protein in cerebrospinal fluid: a possible marker of poor outcome in patients with early relapsing-remitting multiple sclerosis.Neurosci Lett. 2004 Jun 3;363(1):14-7. doi: 10.1016/j.neulet.2004.03.039. Neurosci Lett. 2004. PMID: 15157986
-
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.Mult Scler. 2011 Mar;17(3):335-43. doi: 10.1177/1352458510389102. Epub 2010 Dec 6. Mult Scler. 2011. PMID: 21135023
-
Neurofilaments as biomarkers in multiple sclerosis.Mult Scler. 2012 May;18(5):552-6. doi: 10.1177/1352458512443092. Epub 2012 Apr 4. Mult Scler. 2012. PMID: 22492131 Review.
-
[Clinical features of relapsing remitting-multiple sclerosis. Prognostic factors].Rev Neurol. 2002 Dec 1-15;35(11):1067-73. Rev Neurol. 2002. PMID: 12497314 Review. Spanish.
Cited by
-
Recent Advances in Biosensors for Diagnosis of Autoimmune Diseases.Sensors (Basel). 2024 Feb 26;24(5):1510. doi: 10.3390/s24051510. Sensors (Basel). 2024. PMID: 38475046 Free PMC article. Review.
-
Novel therapeutic for multiple sclerosis protects white matter function in EAE mouse model.Front Mol Med. 2023;3:1237078. doi: 10.3389/fmmed.2023.1237078. Epub 2023 Aug 28. Front Mol Med. 2023. PMID: 37933270 Free PMC article.
-
Identification and management of subclinical disease activity in early multiple sclerosis: a review.J Neurol. 2023 Oct 21. doi: 10.1007/s00415-023-12021-5. Online ahead of print. J Neurol. 2023. PMID: 37864717 Review.
-
Neurodegeneration and its potential markers in the diagnosing of secondary progressive multiple sclerosis. A review.Front Mol Neurosci. 2023 Sep 12;16:1210091. doi: 10.3389/fnmol.2023.1210091. eCollection 2023. Front Mol Neurosci. 2023. PMID: 37781097 Free PMC article. Review.
-
The Heterogeneous Multiple Sclerosis Lesion: How Can We Assess and Modify a Degenerating Lesion?Int J Mol Sci. 2023 Jul 5;24(13):11112. doi: 10.3390/ijms241311112. Int J Mol Sci. 2023. PMID: 37446290 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
